Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summaryMarketScreener Strategies

Anaïs Lozach

Analyst
 
share with twitter share with LinkedIn share with facebook
share via e-mail

Comeback of a rising trend ?

Strategy published on 06/14/2018 | 09:34
long trade
Target price hit
Entry price : 282.9DKK | Target : 306DKK | Stop-loss : 271.5DKK | Potential : 8.17%
Novo Nordisk A/S reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term.
Investors have an opportunity to buy the stock and target the DKK 306.
Strengths
  • The share is getting closer to its long-term support in weekly data, at DKK 265, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (DKK)
Sales 2018 111 B
EBIT 2018 46 665 M
Net income 2018 39 109 M
Finance 2018 16 400 M
Yield 2018 2,56%
P/E ratio 2018 19,43
P/E ratio 2019 18,87
EV / Sales 2018 5,18x
EV / Sales 2019 4,94x
Capitalization 593 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart NOVO NORDISK A/S
Duration : Period : Day
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Duration : Period : Week
Novo Nordisk A/S Technical Analysis Chart | MarketScreener